These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 34431578)

  • 21. Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA.
    Ionova Y; Vuong W; Sandoval O; Fong J; Vu V; Zhong L; Wilson L
    Clin Drug Investig; 2022 Jun; 42(6):491-500. PubMed ID: 35604530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC: A US Healthcare Perspective.
    Mehra R; Yong C; Seal B; van Keep M; Raad A; Zhang Y
    J Natl Compr Canc Netw; 2021 Feb; 19(2):153-162. PubMed ID: 33545688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer.
    Liang X; Chen X; Li H; Li Y
    Front Public Health; 2023; 11():1156427. PubMed ID: 37727602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-line tremelimumab plus durvalumab and chemotherapy
    Liu W; Huo G; Chen P
    Front Pharmacol; 2023; 14():1163381. PubMed ID: 37547328
    [No Abstract]   [Full Text] [Related]  

  • 25. Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
    Polyzoi M; Sandhu H; Maervoet J; Yuan Y; Chaudhary MA; Varol N; Lee A; Dale P; Jones C; Lubinga SJ; Penrod JR
    J Med Econ; 2022; 25(1):660-668. PubMed ID: 35658806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis.
    Zheng Z; Fang L; Cai H
    BMJ Open; 2023 Dec; 13(12):e076383. PubMed ID: 38101853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Effectiveness of Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer Using Evidence From the Chest Radiotherapy Extensive-Stage Small Cell Lung Cancer Trial (CREST).
    Patrice GI; Lester-Coll NH; Yu JB; Amdahl J; Delea TE; Patrice SJ
    Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):97-106. PubMed ID: 29029885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
    Berling M; Chaudhary MA; Yuan Y; Varol N; Dale P; Testa E; Klint J; Lee A; Lubinga SJ; Penrod JR
    J Med Econ; 2022; 25(1):703-711. PubMed ID: 35659172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug Pricing of Domestic Anti-PD-L1 Antibody Adebrelimab: Cost-Effectiveness Analysis of the First-Line ES-SCLC Treatment in China.
    Zhou D; Dong X; Zhou Z; Liu Q
    Risk Manag Healthc Policy; 2023; 16():2521-2529. PubMed ID: 38024490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
    Zhou T; Zhang Z; Luo F; Zhao Y; Hou X; Liu T; Wang K; Zhao H; Huang Y; Zhang L
    JAMA Netw Open; 2020 Oct; 3(10):e2015748. PubMed ID: 33074323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-line Immuno-chemotherapy for extensive-stage small-cell lung cancer: A network meta-analysis and cost-effectiveness analysis.
    Zhu Y; Liu K; Yang Q; Zeng M; Peng L
    Front Public Health; 2023; 11():1028202. PubMed ID: 37006537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.
    Mathieu L; Shah S; Pai-Scherf L; Larkins E; Vallejo J; Li X; Rodriguez L; Mishra-Kalyani P; Goldberg KB; Kluetz PG; Theoret MR; Beaver JA; Pazdur R; Singh H
    Oncologist; 2021 May; 26(5):433-438. PubMed ID: 33687763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.
    Asao T; Watanabe S; Tanaka T; Morita S; Kobayashi K
    BMC Cancer; 2022 Nov; 22(1):1135. PubMed ID: 36333680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing.
    Shao T; Zhao M; Liang L; Tang W
    BioDrugs; 2023 May; 37(3):421-432. PubMed ID: 36840914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China.
    Liu Q; Luo X; Peng L; Yi L; Wan X; Zeng X; Tan C
    BMJ Open; 2020 Nov; 10(11):e040691. PubMed ID: 33243806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. US cost-utility model of lenacapavir plus optimized background regimen (OBR) vs fostemsavir plus OBR and ibalizumab plus OBR for people with HIV with multidrug resistance.
    Vardanega V; New E; Mezzio D; Eddowes LA
    J Manag Care Spec Pharm; 2024 Sep; 30(9):1001-1012. PubMed ID: 39213144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Durvalumab: A Review in Extensive-Stage SCLC.
    Al-Salama ZT
    Target Oncol; 2021 Nov; 16(6):857-864. PubMed ID: 34731446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of durvalumab as a maintenance treatment for patients with locally advanced, unresectable, stage Ⅲ nsclc in china.
    Jiang X; Chen J; Zheng M; Jia H
    PLoS One; 2022; 17(6):e0270118. PubMed ID: 35749385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.